610
Participants
Start Date
December 31, 2011
Primary Completion Date
May 31, 2014
Study Completion Date
July 31, 2014
Lesinurad
Tablets, 200 mg QD
Lesinurad
Tablets, 400 mg QD
Placebo
Tablets, Placebo QD
Allopurinol
Tablets
Lausanne
Auckland
Witbank
Soweto
Auckland
Camperdown
Newtown
Parktown
Wollongong
Bay of Plenty
Heidelberg West
Tauranga
Clayton
Garden Place
Genk
Lommel
Durban
Herston
Newlands
Silverglen
Bisbane
Woodville South
East London
Yvoir
Perth
Shenton Park
Gozée
Worcester
Cape Town
Stellenbosch
Paarl
Mouscron
Rondebosch
Radiokop
Beckenham
Kortrijk
Fichardtpark
Brooklyn
Brooklyn
Berlin
A Coruña
Scottdale
Indiana
Washington D.C.
Washington D.C.
Wheaton
Vinnytsia
Cumberland
Richmond
Danville
Winston-Salem
Durham
Shelby
Charlotte
Calabash
Hickory
Spartanburg
Union
Greenville
Greer
Roswell
Dunwoody
Savannah
Fleming Island
Jacksonville
Jacksonville
Jupiter
Boynton Beach
Brandon
Plant City
Tampa
Tampa
Winter Haven
Poltava
Mobile
Spring Hill
Knoxville
Olive Branch
Lexington
Lexington
Lutsk
Columbus
Cleveland
Middleburg Heights
Franklin
Cincinnati
Dayton
Goch
Evansville
Ann Arbor
Flint
Barakaldo
Dnipropetrovsk
Osnabrück
Fargo
Addison
Chicago
Kharkiv
Kharkiv
Louis
Omaha
Mannheim
Little Rock
Jonesboro
Jonesboro
Oklahoma City
Irving
Houston
Sugarland
Austin
Austin
Denver
Munich
Colorado Springs
Glenwood Springs
Meridian
Boise
West Layton
Pheonix
Eichstätt
Mesa
Chandler
Albuquerque
Reno
La Jolla
San Diego
San Diego
Irvine
Anaheim
San Ramon
Roseville
Gold River
Portland
Portland
Seattle
Tacoma
Trumbull
Fall River
Hyannis
Coquitlam
Kamloops
Penticton
Paradise
Halifax
Corunna
Greater Sudbury
Greater Sudbury
Kitchener
Kitchener
London
Thornhill
Toronto
Québec
Kamenz
Dresden
Dresden
Leipzig
Takapuna
Krakow
Bialystok
Elblag
Gmina Końskie
Katowice
Krakow
Poznan
Radom
Warsaw
Warsaw
Wroclaw
Pretoria
Pretoria
Thabazimbi
Mérida
Kyiv
Kyiv
Lead Sponsor
Ardea Biosciences, Inc.
INDUSTRY